149 related articles for article (PubMed ID: 17156591)
21. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs M; Blacklock H; Bell R; Simeone JF; Reitsma DJ; Heffernan M; Seaman J; Knight RD
J Clin Oncol; 1998 Feb; 16(2):593-602. PubMed ID: 9469347
[TBL] [Abstract][Full Text] [Related]
22. Intravenous pamidronic acid: new indications. Useful palliative treatment for osteolysis.
Prescrire Int; 1998 Aug; 7(36):103-5. PubMed ID: 10342945
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
[TBL] [Abstract][Full Text] [Related]
24. Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?
Dranitsaris G
Int J Technol Assess Health Care; 1999; 15(1):108-22. PubMed ID: 10407599
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
Coleman RE
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
[TBL] [Abstract][Full Text] [Related]
26. Intravenous pamidronate: infusion rate and safety.
Tyrrell CJ; Collinson M; Madsen EL; Ford JM; Coleman T
Ann Oncol; 1994; 5 Suppl 7():S27-9. PubMed ID: 7873459
[TBL] [Abstract][Full Text] [Related]
27. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
[TBL] [Abstract][Full Text] [Related]
28. Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. Aredia Multinational Cooperative Group.
Tyrrell CJ
Ann Oncol; 1994; 5 Suppl 7():S37-40. PubMed ID: 7532992
[TBL] [Abstract][Full Text] [Related]
29. Bone disease in myeloma.
Berenson JR
Curr Treat Options Oncol; 2001 Jun; 2(3):271-83. PubMed ID: 12057127
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.
Chen T; Berenson J; Vescio R; Swift R; Gilchick A; Goodin S; LoRusso P; Ma P; Ravera C; Deckert F; Schran H; Seaman J; Skerjanec A
J Clin Pharmacol; 2002 Nov; 42(11):1228-36. PubMed ID: 12412821
[TBL] [Abstract][Full Text] [Related]
31. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
[TBL] [Abstract][Full Text] [Related]
32. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
Gordon S; Helfrich MH; Sati HI; Greaves M; Ralston SH; Culligan DJ; Soutar RL; Rogers MJ
Br J Haematol; 2002 Nov; 119(2):475-83. PubMed ID: 12406088
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of pamidronate in patients with bone metastases.
Leyvraz S; Hess U; Flesch G; Bauer J; Hauffe S; Ford JM; Burckhardt P
J Natl Cancer Inst; 1992 May; 84(10):788-92. PubMed ID: 1573666
[TBL] [Abstract][Full Text] [Related]
34. Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats.
Pongchaidecha M; Daley-Yates PT
Drug Metab Dispos; 1993; 21(1):100-4. PubMed ID: 8095201
[TBL] [Abstract][Full Text] [Related]
35. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.
Desikan R; Veksler Y; Raza S; Stokes B; Sabir T; Li ZJ; Jagannath S
Br J Haematol; 2002 Nov; 119(2):496-9. PubMed ID: 12406092
[TBL] [Abstract][Full Text] [Related]
36. A cost comparison of intramuscular versus intravenous imipenem.
Chin A; Gill MA; Ito MK; Yellin AE; Berne TV; Heseltine PN; Appleman MD
Hosp Pharm; 1989 Nov; 24(11):905-9. PubMed ID: 10296145
[TBL] [Abstract][Full Text] [Related]
37. Zoledronic acid: new preparation. Just a me-too: no advance in hypercalcemia of malignancy.
Prescrire Int; 2002 Oct; 11(61):140-1. PubMed ID: 12378744
[TBL] [Abstract][Full Text] [Related]
38. Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients--the American experience.
Berenson J
Br J Clin Pract Suppl; 1996 Sep; 87():5-7; discussion 13-4. PubMed ID: 8995010
[No Abstract] [Full Text] [Related]
39. Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.
Lockridge L; Papac RJ; Perazella MA
Am J Kidney Dis; 2002 Jul; 40(1):E2. PubMed ID: 12087588
[TBL] [Abstract][Full Text] [Related]
40. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.
Coleman RE; Houston S; Purohit OP; Rubens RD; Kandra A; Ford J
Eur J Cancer; 1998 May; 34(6):820-4. PubMed ID: 9797692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
